Skip to main content

. 1990 Feb;61(2):323–324. doi: 10.1038/bjc.1990.62

Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy.

D B Smith ¹, E S Newlands ¹, O W Spruyt ¹, R H Begent ¹, G J Rustin ¹, B Mellor ¹, K D Bagshawe ¹

PMCID: PMC1971399 PMID: 2138031

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Costall B., Domeney A. M., Naylor R. J., Tattersall F. D. 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology. 1986 Aug;25(8):959–961. doi: 10.1016/0028-3908(86)90030-4. [DOI] [PubMed] [Google Scholar]
Cunningham D., Hawthorn J., Pople A., Gazet J. C., Ford H. T., Challoner T., Coombes R. C. Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet. 1987 Jun 27;1(8548):1461–1463. doi: 10.1016/s0140-6736(87)92208-2. [DOI] [PubMed] [Google Scholar]
Cunningham D., Turner A., Hawthorn J., Rosin R. D. Ondansetron with and without dexamethasone to treat chemotherapy-induced emesis. Lancet. 1989 Jun 10;1(8650):1323–1323. doi: 10.1016/s0140-6736(89)92711-6. [DOI] [PubMed] [Google Scholar]
Kris M. G., Gralla R. J., Clark R. A., Tyson L. B. Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy. J Clin Oncol. 1988 Apr;6(4):659–662. doi: 10.1200/JCO.1988.6.4.659. [DOI] [PubMed] [Google Scholar]
Kris M. G., Gralla R. J., Tyson L. B., Clark R. A., Kelsen D. P., Reilly L. K., Groshen S., Bosl G. J., Kalman L. A. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. Cancer. 1985 Feb 1;55(3):527–534. doi: 10.1002/1097-0142(19850201)55:3<527::aid-cncr2820550310>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
Miner W. D., Sanger G. J. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol. 1986 Jul;88(3):497–499. doi: 10.1111/j.1476-5381.1986.tb10228.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

ACTIONS

RESOURCES